RxDoctor Payments Data

Michael Casciello, MD

Cardiovascular Disease · New Bern, NCNPI 1639166960

Payments from drug & device makers

$11,509in general payments, 2019–2025

Across 680 payments — averaging $16.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Abbott$1K
  • Novartis$1K
  • E.r. Squibb & Sons, L.L.C.$753
  • Johnson & Johnson$680
  • AstraZeneca$648
  • plus $6K from 50 others

What the payments were for

  • Travel & lodging$2412%
  • Food & beverage$11,16397%
  • Education$1051%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,509 in reported general payments places this provider in the 70th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$619,077
Medicare patients
1,740
Services billed
11,283

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban732$607,264
EntrestoSacubitril/Valsartan407$353,214
FarxigaDapagliflozin Propanediol275$185,444
Repatha SureclickEvolocumab151$110,727
CamzyosMavacamten11$92,242
JardianceEmpagliflozin116$91,330
XareltoRivaroxaban100$75,818
Dofetilide346$74,037
Ranolazine ErRanolazine871$67,367
RybelsusSemaglutide38$43,228
WegovySemaglutide26$33,725
BrilintaTicagrelor50$30,667
Metoprolol Succinate1,624$24,195
Rosuvastatin Calcium1,770$20,214
Dabigatran EtexilateDabigatran Etexilate Mesylate68$18,185

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$223$607,264732 claims
NovartisEntresto$1,017$353,214407 claims
AstraZenecaFarxiga, Brilinta$648$216,110325 claims
Boehringer IngelheimJardiance, Pradaxa$434$96,262131 claims
E.r. Squibb & Sons, L.L.C.Camzyos$753$92,24211 claims
Novo NordiskRybelsus, Wegovy$213$76,95264 claims
Johnson & JohnsonXarelto$680$75,818100 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in New Bern

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →